Literature DB >> 16382779

Widespread and abundant alpha-synuclein pathology in a neurologically unimpaired subject.

Laura Parkkinen1, Tuula Pirttilä, Markku Tervahauta, Irina Alafuzoff.   

Abstract

The intracytoplasmic aggregation of alpha-synuclein (alphaS) protein is a common denominator for a group of neurodegenerative disorders currently known as synucleinopathies. It is generally assumed that the incorporation of alphaS protein into compact inclusions compromises the function and viability of its host cell via mechanical disruption. Herein, we report a widespread and abundant alphaS pathology in an elderly subject, whose medical history gave no indication of any neurodegenerative disease. We compared neuronal and glial components in this neurologically unimpaired subject with a patient with a clinical syndrome of dementia with Lewy bodies (DLB) by using a range of antigenic determinants and an in situ end-labeling technique. We detected no differences in vascular pathologies, in gliosis, or in apoptosis that would have explained the incompatible clinical end-points. With respect to the Alzheimer's disease-related changes, the only differences noted were the beta-amyloid aggregates in the putamen found in the DLB patient alone. Our findings suggest that there must be some currently unidentified factors rather than alphaS-positive inclusions that are responsible for the neuronal dysfunction. The alphaS-positive inclusions may well represent detoxified reserves that cells can tolerate for years, and thus prevention of their development could actually accelerate the diseases process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16382779     DOI: 10.1111/j.1440-1789.2005.00644.x

Source DB:  PubMed          Journal:  Neuropathology        ISSN: 0919-6544            Impact factor:   1.906


  27 in total

1.  Alpha-synuclein: prion or prion-like?

Authors:  Rehana K Leak; Matthew P Frosch; Thomas G Beach; Glenda M Halliday
Journal:  Acta Neuropathol       Date:  2019-08-12       Impact factor: 17.088

Review 2.  Neuropathobiology of non-motor symptoms in Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2015-05-15       Impact factor: 3.575

3.  Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but 'failure to fit' is highly dependent on staging system applied.

Authors:  David G Coughlin; Helen Petrovitch; Lon R White; Joseph Noorigian; Kamal H Masaki; G Webster Ross; John E Duda
Journal:  Parkinsonism Relat Disord       Date:  2019-03-28       Impact factor: 4.891

Review 4.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

Review 5.  Innate and adaptive immune responses in Parkinson's disease.

Authors:  Aubrey M Schonhoff; Gregory P Williams; Zachary D Wallen; David G Standaert; Ashley S Harms
Journal:  Prog Brain Res       Date:  2019-12-05       Impact factor: 2.453

Review 6.  Parkinson's disease and parkinsonism: neuropathology.

Authors:  Dennis W Dickson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

7.  Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies.

Authors:  J A Schneider; Z Arvanitakis; L Yu; P A Boyle; S E Leurgans; D A Bennett
Journal:  Brain       Date:  2012-10       Impact factor: 13.501

Review 8.  Update on the pathogenesis of Parkinson's disease.

Authors:  Jörg B Schulz
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 9.  Formation and development of Lewy pathology: a critical update.

Authors:  Kurt A Jellinger
Journal:  J Neurol       Date:  2009-08       Impact factor: 4.849

10.  Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe Consortium.

Authors:  Irina Alafuzoff; Dietmar R Thal; Thomas Arzberger; Nenad Bogdanovic; Safa Al-Sarraj; Istvan Bodi; Susan Boluda; Orso Bugiani; Charles Duyckaerts; Ellen Gelpi; Stephen Gentleman; Giorgio Giaccone; Manuel Graeber; Tibor Hortobagyi; Romana Höftberger; Paul Ince; James W Ironside; Nikolaos Kavantzas; Andrew King; Penelope Korkolopoulou; Gábor G Kovács; David Meyronet; Camelia Monoranu; Tatjana Nilsson; Piero Parchi; Efstratios Patsouris; Maria Pikkarainen; Tamas Revesz; Annemieke Rozemuller; Danielle Seilhean; Walter Schulz-Schaeffer; Nathalie Streichenberger; Stephen B Wharton; Hans Kretzschmar
Journal:  Acta Neuropathol       Date:  2009-02-01       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.